About Us

OUR MISSION

Our mission is to advance the development of innovative targeted alpha and beta radiation therapies by leveraging our state-of-the-art 300 m² facilities, including specialized laboratories authorized to work with radiation. Through a highly skilled scientific team and advanced technology, we aim to accelerate research and the creation of new therapeutic solutions that improve health and quality of life.

OUR SCIENCE

At NucliThera, we develop innovative treatments for metastatic cancers by harnessing the power of short-range radionuclides. Our research utilizes high-energy alpha and beta radiation to destroy malignant cells at a microscopic level.
By pairing these radionuclides with cancer-specific targeting molecules, we deliver highly localized radiation exactly where it is needed. This targeted approach ensures effective tumor destruction while preserving surrounding healthy tissue. Through continuous innovation, NucliThera is defining the next generation of targeted radionuclide therapies.

PIPELINE OVERVIEW

Betalutin - Hematological Cancers

Discovery Preclinical Clinical
CD37 Platform

NextGenCD37 - Hematological Cancers

Discovery Preclinical Clinical
CD37 Platform

NT003 - Undisclosed

Discovery Preclinical Clinical

Proprietary ²¹²Pb-Generator

Discovery Preclinical Clinical

Specialized Facilities

•300 m² state-of-the-art premises, including B- and C-class laboratories authorized for work with radiation, alongside offices and meeting rooms.

•Fully equipped laboratories and a specialized scientific team dedicated to the development of novel targeted alpha- and beta-radiation therapies.

Our Leadership
Team

Ludvik Sandness
CEO - Board Member

20+ years in TRT leadership

•Former Chairman of Nordic Nanovector and Thor Medical

•40+ years in international finance and biotech leadership.

Roy H. Larsen
CTO - Founder, Chairman of the Board

35+ years in TRT development

•Co-founder of Algeta (Xofigo, acquired by Bayer), Nordic Nanovector, Oncoinvent and ARTBIO.

•Pioneer in radiopharmaceutical innovation.

Øyvind Bruland
CMO - Founder

35+ years in TRT development

•Professor Emeritus of Clinical Oncology, University of Oslo.

•Co-founder of Algeta, Nordic Nanovector, Oncoinvent and ARTBIO.

•Leading clinical oncologist and pioneer in radiopharmaceutical innovation.

Ada Repetto-Llamazares
CSO

17+ years in TRT development

•Dual PhD, expert in radioligand therapy R&D with 17+ years experience.

•Proven track record in building up start-ups and high-performing scientific teams.

Morten Lande
Founder-Board member

20+ years in TRT investment

•Proven track record of investing in and supporting innovative targeted radiation therapy companies, including Algeta, Oncoinvent and Thor Medical.

•Long-standing interest in the development of Norwegian life science and radiopharmaceutical companies.

•Valuable experience from company growth and value creation in the biotechnology sector.

•Expert in Bioinformatics/AI

Specialized Team

Combined expertise in drug development, radiochemistry, biology, translational sciences and clinical development.

Anna M. Sæther
IPhD/R. Assoc.

3+ years in TRT development

Jing Wei
Lab Technician

1+ year in TRT development

Roman Generalov
Ppal. Scientist

10+ years in TRT development

Tatiana Reven
Lab Assistant

5+ years in TRT development

Elisabeth Wiig
R. Engineer

4+ years in TRT development

Gennaro Nesso
R.Engineer

1+ year experience in alpha emitters radiochemistry

Nathalie Færøy

3+ year in TRT development